The trajectory of the erectile dysfunction drug presents a complex picture for investors. While the initial introduction generated significant profits, the expiration of its intellectual property protection opened the door to generic competitors, dramatically eroding market share. read more This creates a particular dilemma for drug manufacturers r

The history of Viagra, and its creator copyright, presents a intriguing case study for investors. At first a blockbuster drug, yielding billions in sales , its intellectual property lapse created a deluge of lower-priced alternatives , significantly diminishing its market share . While specific pharmaceutical companies may seek to capitalize on sim